Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

ανά Luke, Jason J.
Τόπος έκδοσης Oncologist (2019)

Considering adjuvant therapy for stage II melanoma

ανά Poklepovic, Andrew S., Luke, Jason J.
Τόπος έκδοσης Cancer (2019)

Dendritic cells, the T cell-inflamed tumor microenvironment and immunotherapy treatment response

ανά Garris, Christopher S., Luke, Jason J.
Τόπος έκδοσης Clin Cancer Res (2020)

Improving Quality and Addressing the Rising Costs of Cancer Care: Two Birds, One Stone

ανά Luke, Jason, Mirkin, Joshua, Bach, Peter
Έκδοση 2011

Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma

ανά Luke, Jason J., Schwartz, Gary K.
Έκδοση 2013

Advances in the Systemic Treatment of Cutaneous Sarcomas

ανά Luke, Jason J, Keohan, Mary-Louise
Έκδοση 2012

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

ανά Luke, Jason J., Hodi, F. Stephen
Έκδοση 2013

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

ανά Luke, Jason J, Ott, Patrick A
Έκδοση 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

ανά Luke, Jason J., Ott, Patrick A.
Τόπος έκδοσης Oncotarget (2015)

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

ανά Sweis, Randy F., Luke, Jason J.
Τόπος έκδοσης Pharmacol Res (2017)

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development

ανά Olson, Daniel J, Luke, Jason J
Τόπος έκδοσης Immunotherapy (2019)

Improving therapy in metastatic uveal melanoma by understanding prior failures

ανά Olson, Daniel J., Luke, Jason J.
Τόπος έκδοσης Oncoscience (2020)

Toll-Like Receptor 9 Agonists in Cancer

ανά Karapetyan, Lilit, Luke, Jason J, Davar, Diwakar
Τόπος έκδοσης Onco Targets Ther (2020)

Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types

ανά Bao, Riyue, Stapor, Daniel, Luke, Jason J.
Τόπος έκδοσης Genome Med (2020)

Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis

ανά Labadie, Brian W., Bao, Riyue, Luke, Jason J.
Τόπος έκδοσης Clin Cancer Res (2018)

PD-1 Blockade in Chinese versus Western Patients with Melanoma

ανά Shoushtari, Alexander N., Bao, Riyue, Luke, Jason J.
Τόπος έκδοσης Clin Cancer Res (2020)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

ανά Trojaniello, Claudia, Luke, Jason J., Ascierto, Paolo A.
Τόπος έκδοσης Front Oncol (2021)

ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

ανά Bao, Riyue, Hernandez, Kyle, Huang, Lei, Luke, Jason John
Τόπος έκδοσης J Immunother Cancer (2020)

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a ran...

ανά Luke, Jason J., Zha, Yuanyuan, Matijevich, Karen, Gajewski, Thomas F.
Τόπος έκδοσης J Immunother Cancer (2016)

High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

ανά Zielinski, Jessica M., Luke, Jason J., Guglietta, Silvia, Krieg, Carsten
Τόπος έκδοσης Front Immunol (2021)